实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (4): 557-560.doi: 10.3969/j.issn.1672-5069.2026.04.020

• 药物性肝损伤 • 上一篇    下一篇

多烯磷脂酰胆碱胶囊联合复方甘草酸苷片治疗乳腺癌患者化疗药物性肝损伤疗效研究*

许艳, 谭琴, 周晓秋, 孔丽霞, 刘立华, 孙舒   

  1. 214000 江苏省无锡市 联勤保障部队第904医院药剂科(许艳,孙舒,周晓秋,孔丽霞);血液肿瘤科(谭琴);苏州大学附属无锡市第九人民医院药学部(刘立华)
  • 收稿日期:2025-05-02 出版日期:2026-07-10 发布日期:2026-07-20
  • 通讯作者: 孙舒,E-mail:shuasun@163.com
  • 作者简介:许艳,女,38岁,大学本科,药师。E-mail:15190319576@163.com
  • 基金资助:
    *江苏省自然科学基金资助项目(编号:BK20231184)

Efficacy of polyene phosphatidylcholine and glycyrrhizin combination in the treatment of patients with chemotherapy-induced liver injury

Xu Yan, Tan Qin, Zhou Xiaoqiu, et al   

  1. Department of Pharmacy, 904th Hospital, Joint Logistics Support Force, Wuxi 214000, Jiangsu Province, China
  • Received:2025-05-02 Online:2026-07-10 Published:2026-07-20

摘要: 目的 观察多烯磷脂酰胆碱胶囊联合复方甘草酸苷片治疗乳腺癌患者化疗药物性肝损伤(DILI)的临床疗效。方法 2022年1月~2024年12月我院诊治的新发乳腺癌患者98例,均接受手术和术后标准化的蒽环类联合化疗方案治疗4个周期。给予DILI患者多烯磷脂酰胆碱胶囊联合复方甘草酸苷片治疗4~8 w。结果 本组98例乳腺癌患者在化疗过程中出现DILI 者57例(58.2%);DILI组基线BMI、合并高血压、糖尿病和III~IV期肿瘤占比分别为(25.4±2.7)kg/m2、24.6%、19.3%和56.1%,均显著高于或大于与非DILI组【分别为(23.5±2.3)kg/m2、7.3%、4.9%和29.3%,P<0.05】;在57例DILI患者中,肝细胞损伤型、胆汁淤积型和混合型分别为24例、22例和11例,其中<3级肝损伤者45例,≥3级者12例;≥3级肝损伤者治疗时间为(47.5±8.0)d,显著长于<3级者【(22.6±4.5)d,P<0.05】;1例患者发生肝衰竭死亡,其他全部肝功能指标恢复正常。结论 应用多烯磷脂酰胆碱胶囊联合复方甘草酸苷片治疗在化疗过程中患DILI的乳腺癌患者疗效较好,值得继续扩大临床验证。

关键词: 药物性肝损伤, 乳腺癌, 化疗, 多烯磷脂酰胆碱, 复方甘草酸苷, 治疗

Abstract: Objective The aim of this study was to investigate evaluate the efficacy ofpolyene phosphatidylcholine and glycyrrhizin combination in the treatment of patients with chemotherapy-induced liver injury. Methods A total of 98 patients with naïve diagnosed breast cancer were encountered in our hospital between January 2022 and December 2024, all received surgical resection of tumors, and standardized anthracycline-based combination chemotherapy post-operationally for four circles. The patients with drug-induced liver injures (DILI) were managed with oral polyene phosphatidylcholine and glycyrrhizin combination for four to eight weeks. Results Of the 98 patients with breast cancer, DILI occurred in 57 cases (58.2%) during antitumor chemotherapy; baseline body mass index, percentages of concomitant hypertension, diabetes, and stage III/IV tumors in patients with DILI were (25.4±2.7)kg/m2, 24.6%, 19.3% and 56.1%, all significantly greater or higher than [(23.5±2.3)kg/m2, 7.3%, 4.9% and 29.3%, respectively, P<0.05] in those without DILI; of the 57 patients with DILI, we found hepatocellular type in 24 cases, cholestatic type in 22 cases and mixed type in 11 cases, with<grade 3 in 45 cases and ≥grade 3 in 12 cases; the recovery time in patients with ≥grade 3 liver injury was (47.5±8.0)d, much longer than [(22.6±4.5)d, P<0.05] in those with <grade 3; all but one, who died of liver failure, got their liver function tests back to normal. Conclusion Oral polyene phosphatidylcholine and glycyrrhizin combination in dealing with DILI in patients with breast cancer during chemotherapy has a satisfactory efficacy, which merits broaden clinical investigation.

Key words: Drug-induced liver injury, Chemotherapy, Breast cancer, Polyene phosphatidylcholine, Glycyrrhizin, Therapy